imaGeneBio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12526 High Bluff Dr Ste 345, San Diego, ...Website
www.imagenebio.comRevenue
-Stock Symbol
IMAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About imaGeneBio
ImageneBio, Inc. is a global clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company is dedicated to advancing differentiated treatment approaches that target key immune pathways involved in T cell activation and inflammatory disease progression. ImageneBio's pipeline is designed to address conditions with significant unmet medical need, including atopic dermatitis and alopecia areata. ImageneBio trades on the NASDAQ under the ticker symbol IMA.Explore more
imaGeneBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is imaGeneBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at imaGeneBio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
imaGeneBio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if imaGeneBio had a recent Job posting/layoffs
Earning: See what the market has to say on imaGeneBio recently announced quarterly report
Product Launch: Get notified when imaGeneBio launches new products
Check if imaGeneBio has recently received funding, and reach out quickly before it becomes old news!
Check out if imaGeneBio is spiking on competitors!
Funding: Get notified immidiatlly once imaGeneBio has new funding data
Recommended Actions
Reach out to Masked Content who joined imaGeneBio as Masked Content
Find 2 more new buyers
Compare Similar Companies to imaGeneBio
Compare insights from companies similar to imaGeneBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
imaGeneBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
imaGeneBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about imaGeneBio.
imaGeneBio Tech Stack
A closer look at the technologies used by imaGeneBio
See more technologies
Most Recent Scoops
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Project
imaGeneBio has engineered IMG-007 with an extended half-life of approximately 35 days, enabling potentially quarterly or longer dosing intervals and opening the possibility of treatment discontinuation for patients achieving low disease activity or remission.
Medical Research, Pharmaceuticals
Project
imaGeneBio has incorporated Fc silencing engineering into IMG-007 to make it T cell preserving and non-depleting, supporting a better safety profile and enabling dose escalation and therapeutic index exploration.
Engineering
Project
Medical Research, Pharmaceuticals, Clinical Operations
imaGeneBio News & Media
ImageneBio Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update.ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companiesImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding imaGeneBio
Sign Up For FreeTo access detailed company insights
ImageneBio, Inc. is a global clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company is dedicated to advancing differentiated treatment approaches that target key immune pathways involved in T cell activa... Read More
